SG11201900561XA - Chemokine receptor modulators and uses thereof - Google Patents
Chemokine receptor modulators and uses thereofInfo
- Publication number
- SG11201900561XA SG11201900561XA SG11201900561XA SG11201900561XA SG11201900561XA SG 11201900561X A SG11201900561X A SG 11201900561XA SG 11201900561X A SG11201900561X A SG 11201900561XA SG 11201900561X A SG11201900561X A SG 11201900561XA SG 11201900561X A SG11201900561X A SG 11201900561XA
- Authority
- SG
- Singapore
- Prior art keywords
- avenue
- international
- apt
- san
- way
- Prior art date
Links
- 102000009410 Chemokine receptor Human genes 0.000 title abstract 2
- 108050000299 Chemokine receptor Proteins 0.000 title abstract 2
- 240000005020 Acaciella glauca Species 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 235000003499 redwood Nutrition 0.000 abstract 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 abstract 1
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 abstract 1
- 241000694533 Recurvirostra Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 February 2018 (01.02.2018) W I P0 I P C T omit 01110011010II 111110lII ow (10) International Publication Number WO 2018/022992 Al (51) International Patent Classification: A61K 31/5377 (2006.01) C07D 401/12 (2006.01) (21) International Application Number: PCT/US2017/044369 (22) International Filing Date: 28 July 2017 (28.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/368,848 29 July 2016 (29.07.2016) US 62/426,087 23 November 2016 (23.11.2016) US (71) Applicant: FLX BIO, INC. [US/US]; 561 Eccles Avenue, South San Francisco, CA 94080 (US). (72) Inventors: BECK, Hilary, Plake; 115 Springdale Way, Emerald Hills, CA 94062 (US). BIANNIC, Berenger; 1600 E 3rd Avenue, Apt 2508, San Mateo, CA 94401 (US). BUI, Minna Hue, Thanh; 2445 25th Avenue, Oakland, CA 94601 (US). HU, Dennis, X.; 3014 Los Prados, Apt. 103, San Mateo, CA 94403 (US). KETCHAM, John, Michael; 817 N. Humboldt Street, Apt. 211, San Mateo, CA 94401 (US). POWERS, Jay, Patrick; 745 Rockaway Beach Avenue, Pacifica, CA 94044 (US). REILLY, Mau- reen, Kay; 85 Richland Avenue, Unit 5, San Francisco, CA 94110 (US). ROBLES-RESENDIZ, Omar; 1 Avocet Drive, Apt. 206, Redwood City, CA 94065 (US). SHUNA- TONA, Hunter, Paul; 79 Melrose Avenue, San Francisco, CA 94131 (US). WALKER, James, Ross; 9326 Ancient Oak Lane, Verona, WI 53593 (US). WUSTROW, David, Juergen; 116 Vallecitos Way, Los Gatos, CA 95032 (US). YOUNAI, Ashkaan; 397 Imperial Way, Apt. 143, Daly City, CA 94015 (US). ZIBINSKY, Mikhail; 1582 Hudson Street, Redwood City, CA 94061 (US). (74) Agent: YVON, Brigitte, L. et al.; Mintz Levin Cohn Fer- ris Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) 1-1 O \" (57) : Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of CCR4 activity. (54) Title: CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF C
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662368848P | 2016-07-29 | 2016-07-29 | |
| US201662426087P | 2016-11-23 | 2016-11-23 | |
| PCT/US2017/044369 WO2018022992A1 (en) | 2016-07-29 | 2017-07-28 | Chemokine receptor modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900561XA true SG11201900561XA (en) | 2019-02-27 |
Family
ID=61016874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900561XA SG11201900561XA (en) | 2016-07-29 | 2017-07-28 | Chemokine receptor modulators and uses thereof |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10179787B2 (en) |
| EP (1) | EP3490565B1 (en) |
| JP (1) | JP6985388B2 (en) |
| KR (1) | KR102566924B1 (en) |
| CN (1) | CN109789146B (en) |
| AU (1) | AU2017302635B2 (en) |
| CA (1) | CA3032133A1 (en) |
| DK (1) | DK3490565T3 (en) |
| ES (1) | ES2925564T3 (en) |
| HU (1) | HUE059242T2 (en) |
| IL (1) | IL264397B2 (en) |
| MX (1) | MX2019001223A (en) |
| NZ (1) | NZ750182A (en) |
| PL (1) | PL3490565T3 (en) |
| PT (1) | PT3490565T (en) |
| RU (1) | RU2768827C2 (en) |
| SG (1) | SG11201900561XA (en) |
| TW (1) | TWI817929B (en) |
| WO (1) | WO2018022992A1 (en) |
| ZA (1) | ZA201900961B (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013082490A1 (en) | 2011-12-01 | 2013-06-06 | Chemocentryx, Inc. | Substituted anilines as ccr(4) antagonists |
| DK3119397T3 (en) | 2014-03-19 | 2022-03-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of PI3K-gamma-mediated disorders |
| MX2018003058A (en) | 2015-09-14 | 2018-08-01 | Infinity Pharmaceuticals Inc | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same. |
| CN109789146B (en) | 2016-07-29 | 2023-04-18 | 拉普特医疗公司 | Chemokine receptor modulators and uses thereof |
| JP2021502345A (en) | 2017-11-06 | 2021-01-28 | ラプト・セラピューティクス・インコーポレイテッド | Anti-cancer agent |
| SG11202007072RA (en) | 2018-01-26 | 2020-08-28 | Rapt Therapeutics Inc | Chemokine receptor modulators and uses thereof |
| US20210002641A1 (en) * | 2018-03-16 | 2021-01-07 | The Regents Of The University Of Michigan | Compositions and methods for treating graves disease |
| CN112292374B (en) * | 2018-05-31 | 2023-01-03 | 信达生物制药(苏州)有限公司 | Novel phosphoinositide 3-kinase inhibitor and preparation method and application thereof |
| CA3104760C (en) * | 2018-06-26 | 2023-09-26 | Kpc Pharmaceuticals, Inc. | Benzimidazole derivatives and use thereof as idh1 inhibitors |
| MX2021002302A (en) | 2018-08-29 | 2021-04-28 | Chemocentryx Inc | Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors. |
| CN109796457B (en) * | 2019-03-28 | 2020-03-06 | 苏州国匡医药科技有限公司 | Preparation method and application of 2- (3- (azetidin-3-yl) piperidin-1-yl) ethyl-1-ol |
| CN112062728A (en) * | 2019-05-25 | 2020-12-11 | 上海鑫凯化学科技有限公司 | Synthetic method of 3, 5-dichloro-6-ethylpyrazine formamide |
| AU2020383625A1 (en) * | 2019-11-13 | 2022-05-05 | Rapt Therapeutics, Inc. | Crystalline forms of C-C chemokine receptor type 4 antagonist and uses thereof |
| BR112022011272A2 (en) * | 2019-12-09 | 2022-09-06 | Imago Biosciences Inc | METHOD OF TREATMENT OF A MYELOPROLIFERATIVE NEOPLASM, METHOD TO REDUCE THE CONCENTRATION OF ONE OR MORE PROTEIN GROWTH FACTORS, METHOD TO REDUCE BONE MARROW CELLULARITY FOR NORMOCELLULARITY, METHOD TO MAINTAIN BONE MARROW BLAST COUNT OR REDUCE MARROW BLAST COUNT BONE, METHOD TO SUPPRESS THE PROLIFERATION OF MALIGNANT MYELOID CELLS, METHOD TO REDUCE MALIGNANT CELL LOAD MEASURED BY MUTANT ALLELE FREQUENCY OF MYELOID CELLS, METHOD TO ELIMINATE MALIGNANT MYELOID CELLS, METHOD TO REDUCE BONE MARROW FIBROSIS, METHODOMATIC ECHO METHODS TO REDUCE PLASMA LEVELS OF ONE OR MORE INFLAMMATORY CYTOKINES, METHOD TO REDUCE MUTANT ALLELE LOAD, METHOD TO REDUCE A PATHOLOGICALLY ELEVATED RBC MASS, METHOD TO REDUCE MALIGNANT MYELOID CELL MASS, METHOD TO REDUCE SIZE OR VOLUME, METHOD OF BATCH TO REDUCE THE AMOUNT OF EXTRAMEDULAR HEMATOPOIESIS, METHOD TO REDUCE FREQUENCY OF THROMBOSIS AND HEMORRHAGE AND METHOD TO REDUCE THE CONSTITUTIONAL SYMPTOMS OF MYELOFIBROSIS |
| CN111471025A (en) * | 2020-03-26 | 2020-07-31 | 兰州康寓信生物科技有限公司 | Favipiravir intermediate and synthesis method of favipiravir |
| CN111732572B (en) * | 2020-07-31 | 2020-11-13 | 苏州国匡医药科技有限公司 | Preparation method of chiral antitumor drug FLX475 and intermediate thereof |
| CN115466244B (en) * | 2021-06-10 | 2024-08-02 | 武汉伯瑞恒医药科技有限公司 | Chemokine receptor CCR4 antagonists, intermediates, methods of preparation, pharmaceutical compositions and uses thereof |
| MX2024008057A (en) | 2021-12-30 | 2024-08-28 | Biomea Fusion Inc | Pyrazine compounds as inhibitors of flt3. |
| AU2023248361A1 (en) * | 2022-04-06 | 2024-10-10 | Rapt Therapeutics, Inc. | Chemokine receptor modulators and uses thereof |
| CN119301112A (en) | 2022-06-02 | 2025-01-10 | 西藏海思科制药有限公司 | Heterocyclic compound CCR4 inhibitor and application thereof |
| WO2024222736A1 (en) * | 2023-04-24 | 2024-10-31 | 浙江华海药业股份有限公司 | Chemokine receptor modulator preparation method and use |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (en) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION |
| EP0495421B1 (en) | 1991-01-15 | 1996-08-21 | Alcon Laboratories, Inc. | Use of carrageenans in topical ophthalmic compositions |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| HUP9901155A3 (en) | 1996-02-13 | 2003-04-28 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
| AU719327B2 (en) | 1996-03-05 | 2000-05-04 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| US7030123B2 (en) | 2000-05-31 | 2006-04-18 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| US20050277627A1 (en) | 2000-07-07 | 2005-12-15 | Arnould Jean C | Colchinol derivatives as vascular damaging agents |
| JP2004504391A (en) | 2000-07-07 | 2004-02-12 | アンギオジェン・ファーマシューティカルズ・リミテッド | Corkinol derivatives as angiogenesis inhibitors |
| AU2002354476A1 (en) * | 2001-12-14 | 2003-06-30 | Japan Tobacco Inc. | Pyrazolopyridine derivatives and medicinal use thereof |
| AU2003252478A1 (en) | 2002-07-10 | 2004-02-02 | Ono Pharmaceutical Co., Ltd. | Ccr4 antagonist and medicinal use thereof |
| WO2005082865A1 (en) * | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | Fused bicyclic pyrimidine derivative |
| US7514463B2 (en) | 2004-08-20 | 2009-04-07 | University Of Kansas | Lonidamine analogues and their use in male contraception and cancer treatment |
| NL2000323C2 (en) * | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine derivatives. |
| JP5067364B2 (en) * | 2006-03-24 | 2012-11-07 | アステラス製薬株式会社 | Acylaminopiperidine compounds |
| JP2010208945A (en) * | 2007-06-01 | 2010-09-24 | Mitsubishi Tanabe Pharma Corp | Heterocyclic compound |
| KR101048448B1 (en) * | 2008-11-21 | 2011-07-11 | 한국화학연구원 | Novel pyrazolo [4,3-ｂ] pyridine derivatives or pharmaceutically acceptable salts thereof, preparation methods thereof and pharmaceutical compositions containing the same as active ingredients |
| JP2010126496A (en) * | 2008-11-28 | 2010-06-10 | Mitsubishi Tanabe Pharma Corp | Heterocyclic compound |
| NZ594641A (en) * | 2009-02-26 | 2013-03-28 | Glaxo Group Ltd | Pyrazole derivatives used as ccr4 receptor antagonists |
| TW201125867A (en) * | 2009-10-20 | 2011-08-01 | Cellzome Ltd | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors |
| JP2013525370A (en) * | 2010-04-22 | 2013-06-20 | ヤンセン ファーマシューティカ エヌ．ベー． | Indazole compounds useful as keto hexokinase inhibitors |
| WO2012022681A2 (en) * | 2010-08-20 | 2012-02-23 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors |
| WO2013082490A1 (en) | 2011-12-01 | 2013-06-06 | Chemocentryx, Inc. | Substituted anilines as ccr(4) antagonists |
| DK2785710T3 (en) * | 2011-12-01 | 2017-12-04 | Chemocentryx Inc | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR (4) - ANTAGONISTS |
| WO2014026327A1 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
| WO2016021742A1 (en) * | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
| WO2016192083A1 (en) * | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| CN109789146B (en) | 2016-07-29 | 2023-04-18 | 拉普特医疗公司 | Chemokine receptor modulators and uses thereof |
-
2017
- 2017-07-28 CN CN201780060183.8A patent/CN109789146B/en active Active
- 2017-07-28 SG SG11201900561XA patent/SG11201900561XA/en unknown
- 2017-07-28 WO PCT/US2017/044369 patent/WO2018022992A1/en unknown
- 2017-07-28 CA CA3032133A patent/CA3032133A1/en active Pending
- 2017-07-28 DK DK17835338.9T patent/DK3490565T3/en active
- 2017-07-28 NZ NZ750182A patent/NZ750182A/en unknown
- 2017-07-28 KR KR1020197004851A patent/KR102566924B1/en active IP Right Grant
- 2017-07-28 US US15/662,861 patent/US10179787B2/en active Active
- 2017-07-28 RU RU2019105534A patent/RU2768827C2/en active
- 2017-07-28 ES ES17835338T patent/ES2925564T3/en active Active
- 2017-07-28 PL PL17835338.9T patent/PL3490565T3/en unknown
- 2017-07-28 PT PT178353389T patent/PT3490565T/en unknown
- 2017-07-28 MX MX2019001223A patent/MX2019001223A/en unknown
- 2017-07-28 IL IL264397A patent/IL264397B2/en unknown
- 2017-07-28 TW TW106125505A patent/TWI817929B/en active
- 2017-07-28 JP JP2019526200A patent/JP6985388B2/en active Active
- 2017-07-28 AU AU2017302635A patent/AU2017302635B2/en active Active
- 2017-07-28 EP EP17835338.9A patent/EP3490565B1/en active Active
- 2017-07-28 HU HUE17835338A patent/HUE059242T2/en unknown
-
2018
- 2018-11-19 US US16/195,506 patent/US10604526B2/en active Active
-
2019
- 2019-02-14 ZA ZA2019/00961A patent/ZA201900961B/en unknown
-
2020
- 2020-01-28 US US16/775,192 patent/US20200239480A1/en not_active Abandoned
-
2023
- 2023-11-13 US US18/389,182 patent/US20240199620A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900561XA (en) | Chemokine receptor modulators and uses thereof | |
| SG11201805506YA (en) | Modulators of 5'-nucleotidase, ecto and the use thereof | |
| SG11201809041TA (en) | Compositions and methods for selective protein expression | |
| SG11201805137XA (en) | Virus encoding an anti-tcr-complex antibody or fragment | |
| SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| SG11201809336QA (en) | Anti-pd-l1 antibodies | |
| SG11201907299XA (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
| SG11201903835WA (en) | Antibodies directed against programmed death- 1 (pd-1) | |
| SG11201903674YA (en) | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof | |
| SG11201804694SA (en) | Dual controls for therapeutic cell activation or elimination | |
| SG11201805784PA (en) | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases | |
| SG11201807538PA (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy | |
| SG11201809522WA (en) | Method of nucleic acid sequence determination | |
| SG11201808979UA (en) | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof | |
| SG11201903407XA (en) | Secretable variant immunomodulatory proteins and engineered cell therapy | |
| SG11201808821WA (en) | Agonistic antibodies that bind human cd40 and uses thereof | |
| SG11201804294WA (en) | Tank-binding kinase inhibitor compounds | |
| SG11201901716TA (en) | Adenovirus armed with bispecific t cell engager (bite) | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201806453TA (en) | Improved blood-brain barrier endothelial cells derived from pluripotent stem cells for blood-brain barrier models | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201805828YA (en) | Method of treating c3 glomerulopathy |